Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence

References

• Go A, Hylek E, Phillips K. Prevalence of diagnosed atrial fibrillation in adults. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Bruno A, Trocio J, et al. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Curr Med Res Opin 2016;7995:1-10
   Google Scholar
• Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26:847-57
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. AJC 2009;104:1534-9
   Web of Science ®Google Scholar
• Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 2014;114:1453-68
   PubMed Web of Science ®Google Scholar
• Mantha S, Cabral K, Ansell J. New avenues for anticoagulation in atrial fibrillation. Clin Pharmacol Ther 2013;93:68-77
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Novel oral anticoagulants for atrial fibrillation. Curr Atheroscler Rep 2013;15:1-11
   Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. Silver Spring (MD): U.S. Food and Drug Administration; FDA News Release. 2010
   Google Scholar
• US Food and Drug Administration. FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation. Silver Spring (MD): U.S. Food and Drug Administration; FDA News Release, 2014
   Google Scholar
• US Food and Drug Administration. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. Silver Spring (MD): U.S. Food and Drug Administration; FDA News Release. 2011
   Google Scholar
• Lai A, Davidson N, Galloway SW, et al. Perioperative management of patients on new oral anticoagulants. Br J Surg 2014;101:742-9
   PubMed Web of Science ®Google Scholar
• Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Validation of the R2CHADS2 index in the ROCKET AF. Circulation 2013;127:224-32
   PubMed Web of Science ®Google Scholar
• Laible M, Horstmann S, Rizos T, et al. Prevalence of renal dysfunction in ischaemic stroke and transient ischaemic attack patients with or without atrial fibrillation. Eur J Neurol 2015;22:64-e5
   PubMed Web of Science ®Google Scholar
• Hart RG, Eikelboom JW, Brimble KS, et al. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 2013;29:S71-S8
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-35
   PubMed Web of Science ®Google Scholar
• Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-94
   PubMed Web of Science ®Google Scholar
• Lawrence J, Hung J. Statistical Considerations, ENGAGE AF Trial. Silver Spring (MD): US Food and Drug Administration, 2014:29
   Google Scholar
• Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 2011;20:560-6
   PubMed Web of Science ®Google Scholar
• Helgason CM, Do MA, Nutescu E. Warfarin in patients with stroke and reasons for discontinuation. J Stroke Cerebrovasc Dis 2004;13:70-3
   PubMedGoogle Scholar
• Nelson WW, Milentijevic D, Wang L, et al. Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation. Blood Coagul Fibrinolysis 2016;27:1-8
   PubMed Web of Science ®Google Scholar
• Lind M, Fahlen M, Kosiborod M, et al. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res 2012;129:32-5
   PubMed Web of Science ®Google Scholar
• Brown DL, Masselink AJ, Lalla CD. Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft–Gault equation. Ann Pharmacother 2013;47:1039-44
   PubMed Web of Science ®Google Scholar
• D’Agostino Jr RB. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non randomized control group. Stat Med 1998;17:2265-81
   PubMed Web of Science ®Google Scholar
• Nelson WW, Wang L, Baser O, et al. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. Int J Clin Pharm 2014;37:53-9
   PubMed Web of Science ®Google Scholar
• Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009;20:912-21
   PubMed Web of Science ®Google Scholar
• Grand’Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs 2005;5:291-305
   PubMedGoogle Scholar
• Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010;70:703-12
   PubMed Web of Science ®Google Scholar
• Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-94
   PubMed Web of Science ®Google Scholar
• Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 2014;3:1-10
   Web of Science ®Google Scholar
• Janssen Pharmaceuticals, Inc. Xarelto Dosing and Transition Management. Leverkusen, Germany: Jannsen Pharmaceuticals, Inc., 2015
   Google Scholar